These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26217078)

  • 1. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.
    Xiu P; Dong XF; Li XP; Li J
    World J Gastroenterol; 2015 Jul; 21(27):8262-70. PubMed ID: 26217078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer.
    Chi KN; Zoubeidi A; Gleave ME
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1955-62. PubMed ID: 19012510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
    Zielinski R; Chi KN
    Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
    Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
    Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.
    Blumenstein B; Saad F; Hotte S; Chi KN; Eigl B; Gleave M; Jacobs C
    Cancer Med; 2013 Aug; 2(4):468-77. PubMed ID: 24156019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.
    Wang C; Jin G; Jin H; Wang N; Luo Q; Zhang Y; Gao D; Jiang K; Gu D; Shen Q; Huo X; Hu F; Ge T; Zhao F; Chu W; Shu H; Yao M; Cong W; Qin W
    Oncotarget; 2015 Feb; 6(5):2903-16. PubMed ID: 25609201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
    Al-Asaaed S; Winquist E
    Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential use of custirsen to treat prostate cancer.
    Higano CS
    Onco Targets Ther; 2013; 6():785-97. PubMed ID: 23836992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
    Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
    J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.
    Muhammad LA; Saad F
    Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
    So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
    Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
    Miyake H; Hara I; Fujisawa M; Gleave ME
    Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells.
    Redondo M; García-Aranda M; Roldan MJ; Callejón G; Serrano A; Jiménez E; Téllez T
    Anticancer Drugs; 2015 Jan; 26(1):85-9. PubMed ID: 25144344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
    Zhang J; Wu M; Xu Y; Song Q; Zheng W
    Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
    Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis.
    Wang C; Jiang K; Kang X; Gao D; Sun C; Li Y; Sun L; Zhang S; Liu X; Wu W; Yang P; Guo K; Liu Y
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2308-20. PubMed ID: 23010347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells.
    Liao FT; Lee YJ; Ko JL; Tsai CC; Tseng CJ; Sheu GT
    J Gen Virol; 2009 May; 90(Pt 5):1124-1134. PubMed ID: 19264665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
    Zoubeidi A; Chi K; Gleave M
    Clin Cancer Res; 2010 Feb; 16(4):1088-93. PubMed ID: 20145158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.